← All research

The native conformational landscape and priming mechanism of herpes simplex virus glycoprotein B

Mou Z, Wang S, Swanback L, Pan Y, Tsai T, Ji P, Su J, Sahoo B, et al. · Science advances · 2026 Peer-reviewed Lab study (in vitro) Open access DOI

Read the source →

DOI: 10.1126/sciadv.aed8023 · PMID: 42497258 · PMCID: PMC13398477

Entry updated:

A structural study reports cryo-EM structures of HSV-1 glycoprotein B (gB) taken from virions, finding mainly a prefusion state and a minor intermediate primed state. The authors also captured a further intermediate, the deep-primed state, in a mutant and engineered gB mutants locked in distinct conformations. The work is structural and laboratory-based; no immunization or protection data are reported, and the authors frame the mutants as intended for future vaccine evaluation.

Our summary was checked against the full text of the source.

The authors describe stabilizing gB in its prefusion conformation as a primary strategy for vaccine development. In the virion-derived sample, the predominant population (73% of particles) exhibited a compact central helix bundle with a closed tip, while the minor population (27%) displayed a cracked appearance. The authors state they cannot rule out that this difference simply reflects the intrinsic dynamics of gB.

A tethering helix, described as unique to alpha-herpesviruses, cross-links adjacent protomers and stabilizes these conformations. A mutant designed to disrupt this helix lost the ability to induce cell-cell fusion in a virus-free assay and showed only the postfusion structure. The authors engineered mutants locked in distinct conformational states, with one mutant showing only primed particles.

The authors describe these mutants as intended for future vaccine evaluation, and whether they would work as vaccine immunogens is not reported.

Sources

  1. The native conformational landscape and priming mechanism of herpes simplex virus glycoprotein B — Science advances , 2026
How this entry was checked

This entry was drafted with AI assistance and then checked. Every statement below was matched, word for word, to a passage in the full text of the source by software (14 passages and 2 numbers traced). A separate AI pass, run independently and shown only the source and the statements, then tried to find errors (supported by the source, Sep 29, 2026). The editor (Mark) read and approved it on Sep 30, 2026. This is an editorial check, not peer review.

  1. The authors determined cryo-EM structures of HSV-1 glycoprotein B (gB) taken from virions, finding mainly a prefusion state and a minor intermediate primed state. — source P1, P1; Supported by the source
  2. In the virion-derived sample, the predominant population had a compact, closed central helix bundle and a minor population had a cracked appearance. — source P6, P6; Supported by the source
  3. A tethering helix, described as unique to alpha-herpesviruses, cross-links adjacent protomers and stabilizes these conformations. — source P1; Supported by the source
  4. A gB mutant designed to disrupt the tethering helix lost the ability to induce cell-cell fusion in a virus-free assay and showed only the postfusion structure. — source P13, P13; Supported by the source
  5. A further downstream intermediate, named the deep-primed state, was captured in a mutant. — source P1; Supported by the source
  6. The authors engineered gB mutants locked in distinct conformational states; one mutant showed only primed particles. — source P1, P26; Supported by the source
  7. The authors state they cannot rule out that the closed-versus-open difference simply reflects intrinsic gB dynamics rather than a distinct primed state. — source P6; Supported by the source
  8. The authors frame the structures as a basis for designing gB-based vaccines; the mutants are described as intended for future vaccine evaluation. — source P1, P25; Supported by the source
  9. The authors describe stabilizing gB in its prefusion conformation as a primary strategy for vaccine development. — source P1; Supported by the source

Limits noted: in vitro.

See our methodology for how AI assistance is used on this site.